Showing 71-80 of 5938 results for "".
Rethinking Sebum and Its Role in Acne
https://practicaldermatology.com/topics/acne-rosacea/quality-over-quantity-rethinking-sebum-and-its-role-in-acne/23736/In follow-up to a recent column about the function of sebaceous glands, here’s a closer look at sebum itself.Improving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.Optimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.JAK Inhibitors in Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/jak-inhibitors-vitiligo-treatment/24559/Dr. Ted Lain, a dermatologist practicing in Austin, Texas, talks with Practical Dermatology about the latest developments and the promise of Janus kinase (JAK) inhibitors for the treatment of vitiligo. Dr. Lain covers the current impact of JAK inhibitors, their mechanism of action, how he's using thDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thAn Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thFinally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."DermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P